lp-300
Generic: Sodium 2,2'-disulfanediyldiethanesulfonate
lp-300: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Lantern Pharma Inc. (LTRN) | Phase 2 |
Clinical Trials (1)
Phase II Trial of LP-300 in Combination With Carboplatin and Pemetrexed in Never Smoker Patients With Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment With Tyrosine Kinase Inhibitors (The HARMONIC Study)
Frequently asked questions
Who is developing lp-300?
lp-300 is being developed by Lantern Pharma Inc..
How many clinical trials involve lp-300?
BioSniper tracks 1 clinical trial involving lp-300.
Get deeper analysis on lp-300
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis